Andere Sprachen Hemogenyx Pharmaceuticals Plc

Aktien

A143YN

GB00BYX3WZ24

SILF

Markt geschlossen - London S.E. Andere Börsenplätze 17:35:10 26.04.2024			% 5 Tage	% 1. Jan.
1.65 ^GBX	+4.10%		+0.55%	-28.26%

25.04.	Hemogenyx Pharmaceuticals Plc berichtet über die Ergebnisse für das am 31. Dezember 2023 endende Geschäftsjahr	CI
29.02.	Hemogenyx Pharmaceuticals sammelt Geld für Leukämie-Behandlung	AN

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

EARNINGS: LSL starts 2024 "strongly"; Focusrite maintains payout	25.04.
Hemogenyx Pharmaceuticals Plc Reports Earnings Results for the Full Year Ended December 31, 2023	25.04.
Hemogenyx Pharmaceuticals discusses successful Ã‚£3.5M capital raise as it advances HEMO-CAR-T program	12.03.
Hemogenyx Pharmaceuticals raises money for leukaemia treatment	29.02.
Hemogenyx Pharmaceuticals Raises $4.2 Million via Share Placing	29.02.
Hemogenyx Pharmaceuticals achieves breakthrough with HEMO-CAR-T program, CBR platform	20.02.
Hemogenyx Pharmaceuticals PLC Announces CBR Brain Delivery	19.02.
Hemogenyx Pharmaceuticals Achieves Breakthrough in Brain Cancer Treatment	16.02.
Hemogenyx shares rise on potential for CBR to treat brain diseases	16.02.
Hemogenyx Pharmaceuticals plc Announces CBR Brain Delivery	16.02.
Hemogenyx Pharmaceuticals Tests Intranasal Delivery for Viral Infections Treatment	14.02.
Hemogenyx says CBR can be used intranasally to treat viral infections	14.02.
Hemogenyx shares surge as FDA lifts Hemo-Car-T trial hold	09.02.
US FDA Removes Clinical Hold on Hemogenyx Pharmaceuticals' Acute Myeloid Leukemia Treatment	09.02.
Hemogenyx Pharmaceuticals PLC Announces FDA Consents to Phase I Trials of HEMO-CAR-T	09.02.
Hemogenyx Pharmaceuticals Obtains US Conditioning Patent	02.02.
Hemogenyx hails US patent application progress	02.02.
Hemogenyx Pharmaceuticals plc Announces Approval and Issuance of U.S. Conditioning Patent	02.02.
Hemogenyx Pharmaceuticals plc - Submission of Complete Response to Clinical Hold for HEMO-CAR-T IND	17.01.
Hemogenyx Pharmaceuticals sends complete response on HEMO-CAR-T to FDA	16.01.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Hemogenyx Pharmaceuticals Plc

Aktien

A143YN

GB00BYX3WZ24

SILF

Andere Sprachen

Filter